Celldex 药物在湿疹试验中失败;nChroma Bio 裁员
Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
Celldex Therapeutics 的 top 药物 barzolvolimab 在湿疹试验中未能达到预期效果,将停止开发。nChroma Bio 将暂停其乙肝项目并裁员,考虑战略选择。Isomorphic Labs 与 Merck 合作开发癌症疗法,但未披露具体细节和财务条款。
An article from
News roundup
Wall Street analysts rushed to Celldex’s defense following the setback. Elsewhere, Isomorphic Labs cut a cancer-focused deal with Merck and Teva’s research chief accepted a new job.
Published Nov. 20, 2026
Today, a brief rundown of news involving Celldex Therapeutics and nChroma Bio, as well as updates from Isomorphic Labs, Teva and VitriVax that you may have missed.
Celldex Therapeutics will stop developing its top drug barzolvolimab in eczema after the therapy didn't prove impactful enough in a Phase 2 study. Celldex is already planning an approval filing for barzolvolimab in a form of chronic hives following success in a pair of late-stage trials. But the drug has fallen short in Phase 2 testing in two other immune conditions and, on Thursday, didn't meet the company's "internal hurdle rate" for continued development in eczema, Celldex said. Several Wall Street analysts rushed to Celldex's defense, claiming expectations were low for the study and that its failure is "immaterial" to the investment case in the company. The "key debate" ahead for Celldex is barzolvolimab's place in the "growing" market for chronic spontaneous urticaria treatments, wrote Stifel analyst Alex Thompson.
NChroma Bio halted testing of its lead program in hepatitis B and will evaluate "strategic alternatives" for its work. In a LinkedIn post, the company also disclosed plans to cut staff and restructure while pursuing the "best path forward" for its drug research. NChroma was formed through a 2024 merger between Chroma Medicine and Nvelop Therapeutics, a deal that combined epigenetic editing technology with a delivery system built on non-viral particles. It had been positioning its top prospect, CRMA-1001, as a possible "functional cure" for chronic hepatitis B infections. The company will reportedly lay off around half its workforce. NChroma downsized last year as well.
Two days after closing a $5 billion venture financing, AI drug discovery specialist Isomorphic Labs revealed a secretive, cancer-focused collaboration with Merck & Co. The two companies didn’t disclose the financial terms of the arrangement in their Thursday announcement, or the specifics of the would-be drugs involved. They only said that they’ll team up to develop small molecule cancer therapies against an unspecified target of “strategic importance,” Merck will cover development costs for the programs that arise, and Isomorphic stands to receive certain milestone payments and royalties. Isomorphic also has alliances in place with Eli Lilly, Johnson & Johnson and Novartis.
Eric Hughes, Teva Pharmaceutical's R&D chief and chief medical officer, has accepted a new job offer and is leaving the company. Teva said Wednesday that David Gardiner, its head of innovative medicines and clinical development, will serve in Hughes' role temporarily until the company names a permanent successor. The news took Wall Street by surprise, though multiple analysts expressed support for Teva's future. "We remain quite confident in the company's broader clinical organization going forward," wrote Leerink Partners analyst Daniel Clark. Teva reiterated its goal of generating $6 billion to $7 billion in revenue from branded medicines by 2030.
VitriVax on Wednesday secured $87 million in Series C financing to develop a new kind of Lyme disease vaccine. VitriVax said its shot is designed to provide broad protection with a single dose and could be administered without the help of an immune-boosting adjuvant, which could reduce side effects and lower production costs. The funds, provided by F-Prime Capital, RA Capital Management, NEA as well as Eli Lilly and Sanofi's venture arm, will help the company start its first human trial.
来源:BioPharma Dive · biopharmadive.com